Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | ACP1 | P24666 | 3/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335290 | 0.90 | CDK1 (0.52) | GSK3BCDK1CDK2ACHEACP1 | |
| SCHEMBL1378947 | 0.82 | GSK3B (0.70) | GSK3BCDK1CDK2ACHECDC7 | |
| SCHEMBL2337764 | 0.81 | GSK3B (0.60) | GSK3BCDK1CDK2POLB | |
| SCHEMBL1375621 | 0.81 | GSK3B (0.64) | GSK3BCDK1CDK2MEN1KMT2A | |
| SCHEMBL1461071 | 0.81 | GSK3B (0.52) | GSK3BCDK1CDK2ACHEACP1 | |
| SCHEMBL2338246 | 0.80 | GSK3B (0.59) | GSK3BCDK1CDK2CDC7 | |
| SCHEMBL2333642 | 0.80 | GSK3B (0.67) | GSK3BCDK1CDK2ACP1POLB | |
| SCHEMBL2334940 | 0.80 | GSK3B (0.56) | GSK3BCDK1CDK2ACHEMEN1 | |
| SCHEMBL2338648 | 0.79 | GSK3B (0.58) | GSK3BCDK1CDK2CDC7HPGD | |
| SCHEMBL2335996 | 0.79 | GSK3B (0.60) | GSK3BCDK1CDK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4764168-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| EP-1572200-B1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-08-17 | — | — | EP | claimed |
| CN-101979382-A | Aminoindazole derivatives and use thereof as kinase inhibitors | AVENTIS PHARMA SA | 2011-02-23 | — | — | CN | claimed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | claimed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | claimed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | claimed |
| CN-1713909-A | Aminoindazole derivatives and their use as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-12-28 | — | — | CN | claimed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | claimed |
| EP-1572200-B1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-08-17 | — | — | EP | disclosed |
| CN-101979382-A | Aminoindazole derivatives and use thereof as kinase inhibitors | AVENTIS PHARMA SA | 2011-02-23 | — | — | CN | disclosed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7407981-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7196109-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | disclosed |
| CN-1713909-A | Aminoindazole derivatives and their use as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-12-28 | — | — | CN | disclosed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | OXSR1, CBR1, OXER1 | GSK3B 159/4885CDK1 63/4885CDK2 549/4885 |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | SIGMAR1, CYP2C8, CNR1 | GSK3B 3595/4885CDK1 2123/4885CDK2 2237/4885 |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.